Paul Resnick

Vice President of Business Development
Juventas Therapeutics

Paul Resnick, M.D., M.B.A. (Vice President, Business Development) leads Juventas' business and commercial development. Prior to Juventas, Dr. Resnick led business development for Intellikine, culminating in its acquisition by Takeda Pharmaceuticals. He previously held roles at Pfizer, Rinat Neuroscience (acquired by Pfizer), InterMune, and Roche and also practiced medicine. Dr. Resnick's professional experience includes product and business development with solid performance leading and executing business strategy resulting in transforming collaborations. Dr. Resnick earned a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Doctor of Medicine from the Medical College of Wisconsin.

Check out the incredible speaker line-up to see who will be joining Paul.

Download The Latest Agenda

Day 3

Tuesday, May 10th, 2016

11:00 PANEL: Exploring Opportunities In Converging Drug-Device Technologies And Their Place In BioPharma Future

• Examining the current state of drug-device combination products and how the technology, regulatory processes, and purchasers are coming together

• Are drug-device combos rarities or are they truly the wave of the future? The commonality of emerging biologic-device combination and solutions

• Uncovering how the industry will need to shift to support drug-device convergence technologies and what biopharma can do to enable this innovation

• Stories from the trenches: from customer selection and staffing the organization, to building your team and how best to approach the buying universe when its time to sell

o Selection of proprietary vs. off-the-shelf solutions vs. combinations